SCHEMBL16690348

SCHEMBL16690348

Cn1nnn(-c2ccccc2OCc2ccccc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.51
PKM P14618 3/20 0.46
HTR1A P08908 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
MAPK14 Q16539 3/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
LIPE Q05469 1/20 0.41
HTR6 P50406 1/20 0.40
ATP4A P20648 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16690368 0.90 MEN1 (0.44) BRD4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16690430 0.84 GRM5 (0.38) BRD4PKMHTR1AMAPK14
SCHEMBL18037163 0.82 DGAT1 (0.41) BRD4ADORA3RXRARXRBRXRG
SCHEMBL16690360 0.82 BRD4 (0.41) BRD4PKML3MBTL1MAPTMAPK1
SCHEMBL16690405 0.82 PKM (0.43) BRD4PKMHTR1AL3MBTL1MAPT
SCHEMBL16690352 0.81 BRD4 (0.35) BRD4PKMMAPTTDP1SMN1; SMN2
SCHEMBL16442751 0.79 FFAR1 (0.43) BRD4PKML3MBTL1TDP1NPC1
SCHEMBL16683811 0.76 MAOB (0.44) PKML3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL16442901 0.76 FFAR4 (0.38) BRD4HTR1AMAPTMRGPRX4LTA4H
SCHEMBL17616622 0.76 MAPT (0.35) BRD4MAPTRAB9AMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3064492-B1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME SUMITOMO CHEMICAL CO (JP) 2018-12-26 EP disclosed
US-10091998-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-10-09 US disclosed
EP-3064492-A1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME Sumitomo Chemical Company, Limited (JP) 2016-09-07 EP disclosed
EP-3064492-A1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME Sumitomo Chemical Company, Limited (JP) 2016-09-07 EP disclosed
US-20160249617-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-09-01 US disclosed
US-20160249617-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-09-01 US disclosed
WO-2015064727-A1 TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME 住友化学株式会社 2015-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160249617-A1 TETRAZOLINONE COMPOUND AND USE THEREOF TCOF1, TAOK2, CYC1 BRD4 2924/4885PKM 2986/4885HTR1A 1442/4885
US-10091998-B2 Tetrazolinone compound and use thereof RO60, MT-CO1, ROS1 BRD4 2717/4885PKM 2682/4885HTR1A 2384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.